Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 290

1.

Most Patients With Celiac Disease on Gluten-free Diets Consume Measurable Amounts of Gluten.

Silvester JA, Comino I, Kelly CP, Sousa C, Duerksen DR; DOGGIE BAG Study Group.

Gastroenterology. 2019 Dec 19. pii: S0016-5085(19)41945-8. doi: 10.1053/j.gastro.2019.12.016. [Epub ahead of print] No abstract available.

PMID:
31866245
2.

Reliability of stemless shoulder arthroplasty in rheumatoid arthritis: observation of early lysis around the humeral component.

Jordan RW, Manoharan G, Van Liefland M, Dodenhoff R, Hay SM, Kelly CP, Potter RP.

Musculoskelet Surg. 2019 Nov 6. doi: 10.1007/s12306-019-00629-8. [Epub ahead of print]

PMID:
31696419
3.

Donor Screening for Fecal Microbiota Transplantation.

Kassam Z, Dubois N, Ramakrishna B, Ling K, Qazi T, Smith M, Kelly CR, Fischer M, Allegretti JR, Budree S, Panchal P, Kelly CP, Osman M.

N Engl J Med. 2019 Nov 21;381(21):2070-2072. doi: 10.1056/NEJMc1913670. Epub 2019 Oct 30. No abstract available.

PMID:
31665572
4.

Effect of Endogenous Clostridioides difficile Toxin Antibodies on Recurrence of C. difficile Infection.

Kelly CP, Poxton IR, Shen J, Wilcox MH, Gerding DN, Zhao X, Laterza OF, Railkar R, Guris D, Dorr MB.

Clin Infect Dis. 2019 Oct 19. pii: ciz809. doi: 10.1093/cid/ciz809. [Epub ahead of print]

PMID:
31628838
5.

Recent developments in the management of recurrent Clostridioides difficile infection.

Mendo-Lopez R, Villafuerte-Gálvez J, White N, Mahoney MV, Kelly CP, Alonso CD.

Anaerobe. 2019 Oct 10:102108. doi: 10.1016/j.anaerobe.2019.102108. [Epub ahead of print] Review.

PMID:
31606481
6.

Laxative use does not preclude diagnosis or reduce disease severity in Clostridiodes difficile infection.

White NC, Mendo-Lopez R, Papamichael K, Cuddemi CA, Barrett C, Daugherty K, Pollock N, Kelly CP, Alonso CD.

Clin Infect Dis. 2019 Oct 4. pii: ciz978. doi: 10.1093/cid/ciz978. [Epub ahead of print]

PMID:
31584632
7.

Inter- and Intra-assay Variation in the Diagnostic Performance of Assays for Anti-tissue Transglutaminase in 2 Populations.

Singh P, Singh A, Silvester JA, Sachdeva V, Chen X, Xu H, Leffler DA, Ahuja V, Duerksen DR, Kelly CP, Makharia GK.

Clin Gastroenterol Hepatol. 2019 Sep 20. pii: S1542-3565(19)31023-7. doi: 10.1016/j.cgh.2019.09.018. [Epub ahead of print]

PMID:
31546060
8.

Celiac Disease: Extraintestinal Manifestations and Associated Conditions.

Therrien A, Kelly CP, Silvester JA.

J Clin Gastroenterol. 2020 Jan;54(1):8-21. doi: 10.1097/MCG.0000000000001267.

PMID:
31513026
9.

Prevention of recurrent Clostridioides difficile infection: A systematic review of randomized controlled trials.

Madoff SE, Urquiaga M, Alonso CD, Kelly CP.

Anaerobe. 2019 Sep 4:102098. doi: 10.1016/j.anaerobe.2019.102098. [Epub ahead of print] Review.

PMID:
31493500
10.

Toxin A-predominant Pathogenic C. difficile: A Novel Clinical Phenotype.

Lin Q, Pollock NR, Banz A, Lantz A, Xu H, Gu L, Gerding DN, Garey KW, Gonzales-Luna AJ, Zhao M, Song L, Duffy DC, Kelly CP, Chen X.

Clin Infect Dis. 2019 Aug 11. pii: ciz727. doi: 10.1093/cid/ciz727. [Epub ahead of print]

PMID:
31400280
11.

External rotation bracing for first-time anterior dislocation of the shoulder: A discontinued randomised controlled trial comparing external rotation bracing with conventional sling.

Chan SK, Bentick KR, Kuiper JH, Kelly CP.

Shoulder Elbow. 2019 Aug;11(4):256-264. doi: 10.1177/1758573218768521. Epub 2018 Apr 26.

PMID:
31316586
12.

Natural Clostridioides difficile toxin immunization in colonized infants.

Kociolek LK, Espinosa RO, Gerding DN, Hauser AR, Ozer EA, Budz M, Balaji A, Chen X, Tanz RR, Yalcinkaya N, Conner ME, Savidge T, Kelly CP.

Clin Infect Dis. 2019 Jun 29. pii: ciz582. doi: 10.1093/cid/ciz582. [Epub ahead of print]

PMID:
31253983
13.

Host Immune Markers Distinguish Clostridioides difficile Infection From Asymptomatic Carriage and Non-C. difficile Diarrhea.

Kelly CP, Chen X, Williams D, Xu H, Cuddemi CA, Daugherty K, Barrett C, Miller M, Foussadier A, Lantz A, Banz A, Pollock NR.

Clin Infect Dis. 2019 Apr 26. pii: ciz330. doi: 10.1093/cid/ciz330. [Epub ahead of print]

PMID:
31211839
14.

Novel Nondietary Therapies for Celiac Disease.

Alhassan E, Yadav A, Kelly CP, Mukherjee R.

Cell Mol Gastroenterol Hepatol. 2019;8(3):335-345. doi: 10.1016/j.jcmgh.2019.04.017. Epub 2019 May 27. Review.

15.

Efficacy of Enteric-Release Oral Budesonide in Treatment of Acute Reactions to Gluten in Patients With Celiac Disease.

Therrien A, Silvester JA, Leffler DA, Kelly CP.

Clin Gastroenterol Hepatol. 2020 Jan;18(1):254-256. doi: 10.1016/j.cgh.2019.03.029. Epub 2019 Mar 21.

PMID:
30905717
16.

Saccharomyces boulardii CNCM I-745 Modulates the Fecal Bile Acids Metabolism During Antimicrobial Therapy in Healthy Volunteers.

Kelly CP, Chong Nguyen C, Palmieri LJ, Pallav K, Dowd SE, Humbert L, Seksik P, Bado A, Coffin B, Rainteau D, Kabbani T, Duboc H.

Front Microbiol. 2019 Mar 4;10:336. doi: 10.3389/fmicb.2019.00336. eCollection 2019.

17.

Nondietary Therapies for Celiac Disease.

Serena G, Kelly CP, Fasano A.

Gastroenterol Clin North Am. 2019 Mar;48(1):145-163. doi: 10.1016/j.gtc.2018.09.011. Epub 2018 Dec 13. Review.

PMID:
30711207
18.

Clostridium difficile toxins induce VEGF-A and vascular permeability to promote disease pathogenesis.

Huang J, Kelly CP, Bakirtzi K, Villafuerte Gálvez JA, Lyras D, Mileto SJ, Larcombe S, Xu H, Yang X, Shields KS, Zhu W, Zhang Y, Goldsmith JD, Patel IJ, Hansen J, Huang M, Yla-Herttuala S, Moss AC, Paredes-Sabja D, Pothoulakis C, Shah YM, Wang J, Chen X.

Nat Microbiol. 2019 Feb;4(2):269-279. doi: 10.1038/s41564-018-0300-x. Epub 2018 Dec 3.

19.

Novel Chimeric Protein Vaccines Against Clostridium difficile Infection.

Wang S, Wang Y, Cai Y, Kelly CP, Sun X.

Front Immunol. 2018 Oct 22;9:2440. doi: 10.3389/fimmu.2018.02440. eCollection 2018.

20.

Bezlotoxumab for Clostridium difficile Infection Complicating Inflammatory Bowel Disease.

Kelly CP, Wilcox MH, Glerup H, Aboo N, Ellison MC, Eves K, Dorr MB.

Gastroenterology. 2018 Oct;155(4):1270-1271. doi: 10.1053/j.gastro.2018.06.080. Epub 2018 Sep 15. No abstract available.

21.

Diagnostic Accuracy of Point of Care Tests for Diagnosing Celiac Disease: A Systematic Review and Meta-Analysis.

Singh P, Arora A, Strand TA, Leffler DA, Mäki M, Kelly CP, Ahuja V, Makharia GK.

J Clin Gastroenterol. 2019 Aug;53(7):535-542. doi: 10.1097/MCG.0000000000001081.

PMID:
29912751
22.

TPL2 Is a Key Regulator of Intestinal Inflammation in Clostridium difficile Infection.

Wang Y, Wang S, Kelly CP, Feng H, Greenberg A, Sun X.

Infect Immun. 2018 Jul 23;86(8). pii: e00095-18. doi: 10.1128/IAI.00095-18. Print 2018 Aug.

23.

Comparison of Clostridioides difficile Stool Toxin Concentrations in Adults With Symptomatic Infection and Asymptomatic Carriage Using an Ultrasensitive Quantitative Immunoassay.

Pollock NR, Banz A, Chen X, Williams D, Xu H, Cuddemi CA, Cui AX, Perrotta M, Alhassan E, Riou B, Lantz A, Miller MA, Kelly CP.

Clin Infect Dis. 2019 Jan 1;68(1):78-86. doi: 10.1093/cid/ciy415.

24.

Revision shoulder arthroplasty for failed surface replacement hemiarthroplasty.

Jaiswal A, Malhotra A, Hay S, Kelly CP.

Musculoskelet Surg. 2019 Apr;103(1):69-75. doi: 10.1007/s12306-018-0541-0. Epub 2018 May 9.

PMID:
29744735
25.

On and Off: A Dual Role for Cysteine Protease Autoprocessing of C difficile Toxin B on Cytotoxicity vs Proinflammatory Toxin Actions?

Chen X, Kelly CP.

Cell Mol Gastroenterol Hepatol. 2018 Mar 21;5(4):654-655. doi: 10.1016/j.jcmgh.2018.02.011. eCollection 2018. No abstract available.

26.

Global Prevalence of Celiac Disease: Systematic Review and Meta-analysis.

Singh P, Arora A, Strand TA, Leffler DA, Catassi C, Green PH, Kelly CP, Ahuja V, Makharia GK.

Clin Gastroenterol Hepatol. 2018 Jun;16(6):823-836.e2. doi: 10.1016/j.cgh.2017.06.037. Epub 2018 Mar 16.

PMID:
29551598
27.

Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence.

Gerding DN, Kelly CP, Rahav G, Lee C, Dubberke ER, Kumar PN, Yacyshyn B, Kao D, Eves K, Ellison MC, Hanson ME, Guris D, Dorr MB.

Clin Infect Dis. 2018 Aug 16;67(5):649-656. doi: 10.1093/cid/ciy171.

28.

Determination of gluten consumption in celiac disease patients on a gluten-free diet.

Syage JA, Kelly CP, Dickason MA, Ramirez AC, Leon F, Dominguez R, Sealey-Voyksner JA.

Am J Clin Nutr. 2018 Feb 1;107(2):201-207. doi: 10.1093/ajcn/nqx049.

PMID:
29529159
29.

Measuring Change In Small Intestinal Histology In Patients With Celiac Disease.

Adelman DC, Murray J, Wu TT, Mäki M, Green PH, Kelly CP.

Am J Gastroenterol. 2018 Mar;113(3):339-347. doi: 10.1038/ajg.2017.480. Epub 2018 Feb 20. Review.

PMID:
29460921
30.

Self-reported dietary adherence, disease-specific symptoms, and quality of life are associated with healthcare provider follow-up in celiac disease.

Hughey JJ, Ray BK, Lee AR, Voorhees KN, Kelly CP, Schuppan D.

BMC Gastroenterol. 2017 Dec 11;17(1):156. doi: 10.1186/s12876-017-0713-7.

31.

Proton pump inhibitors and risk of Clostridium difficile infection: association or causation?

Villafuerte-Gálvez JA, Kelly CP.

Curr Opin Gastroenterol. 2018 Jan;34(1):11-18. doi: 10.1097/MOG.0000000000000414. Review.

PMID:
29095766
32.

Fidaxomicin and OP-1118 Inhibit Clostridium difficile Toxin A- and B-Mediated Inflammatory Responses via Inhibition of NF-κB Activity.

Koon HW, Wang J, Mussatto CC, Ortiz C, Lee EC, Tran DH, Chen X, Kelly CP, Pothoulakis C.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01513-17. doi: 10.1128/AAC.01513-17. Print 2018 Jan.

33.

Symptoms of Functional Intestinal Disorders Are Common in Patients with Celiac Disease Following Transition to a Gluten-Free Diet.

Silvester JA, Graff LA, Rigaux L, Bernstein CN, Leffler DA, Kelly CP, Walker JR, Duerksen DR.

Dig Dis Sci. 2017 Sep;62(9):2449-2454. doi: 10.1007/s10620-017-4666-z. Epub 2017 Jul 7.

34.

Bezlotoxumab: anti-toxin B monoclonal antibody to prevent recurrence of Clostridium difficile infection.

Villafuerte Gálvez JA, Kelly CP.

Expert Rev Gastroenterol Hepatol. 2017 Jul;11(7):611-622. doi: 10.1080/17474124.2017.1344551. Epub 2017 Jun 26. Review.

PMID:
28636484
35.

Cytokines Are Markers of the Clostridium difficile-Induced Inflammatory Response and Predict Disease Severity.

Yu H, Chen K, Sun Y, Carter M, Garey KW, Savidge TC, Devaraj S, Tessier ME, von Rosenvinge EC, Kelly CP, Pasetti MF, Feng H.

Clin Vaccine Immunol. 2017 Aug 4;24(8). pii: e00037-17. doi: 10.1128/CVI.00037-17. Print 2017 Aug.

36.

Tests for Serum Transglutaminase and Endomysial Antibodies Do Not Detect Most Patients With Celiac Disease and Persistent Villous Atrophy on Gluten-free Diets: a Meta-analysis.

Silvester JA, Kurada S, Szwajcer A, Kelly CP, Leffler DA, Duerksen DR.

Gastroenterology. 2017 Sep;153(3):689-701.e1. doi: 10.1053/j.gastro.2017.05.015. Epub 2017 May 22. Review.

37.

A multicenter, retrospective, case-cohort study of the epidemiology and risk factors for Clostridium difficile infection among cord blood transplant recipients.

Alonso CD, Braun DA, Patel I, Akbari M, Oh DJ, Jun T, McMasters M, Hammond SP, Glotzbecker B, Cutler C, Leffler DA, Ballen KK, Kelly CP.

Transpl Infect Dis. 2017 Aug;19(4). doi: 10.1111/tid.12728. Epub 2017 Jul 12.

PMID:
28544102
38.

A Novel Patient-Derived Conceptual Model of the Impact of Celiac Disease in Adults: Implications for Patient-Reported Outcome and Health-Related Quality-of-Life Instrument Development.

Leffler DA, Acaster S, Gallop K, Dennis M, Kelly CP, Adelman DC.

Value Health. 2017 Apr;20(4):637-643. doi: 10.1016/j.jval.2016.12.016. Epub 2017 Feb 14.

39.

Factors associated with villus atrophy in symptomatic coeliac disease patients on a gluten-free diet.

Mahadev S, Murray JA, Wu TT, Chandan VS, Torbenson MS, Kelly CP, Maki M, Green PH, Adelman D, Lebwohl B.

Aliment Pharmacol Ther. 2017 Apr;45(8):1084-1093. doi: 10.1111/apt.13988. Epub 2017 Feb 20.

40.

Lack of adherence to SHEA-IDSA treatment guidelines for Clostridium difficile infection is associated with increased mortality.

Patel I, Wungjiranirun M, Theethira T, Villafuerte-Galvez J, Castillo N, Akbari M, Alonso CD, Leffler DA, Kelly CP.

J Antimicrob Chemother. 2017 Feb;72(2):574-581. doi: 10.1093/jac/dkw423. Epub 2016 Nov 14.

41.

Management of Clostridium difficile Infection in Inflammatory Bowel Disease: Expert Review from the Clinical Practice Updates Committee of the AGA Institute.

Khanna S, Shin A, Kelly CP.

Clin Gastroenterol Hepatol. 2017 Feb;15(2):166-174. doi: 10.1016/j.cgh.2016.10.024. Review. Erratum in: Clin Gastroenterol Hepatol. 2017 Apr;15(4):607.

PMID:
28093134
42.

Salivary Gluten Degradation and Oral Microbial Profiles in Healthy Individuals and Celiac Disease Patients.

Tian N, Faller L, Leffler DA, Kelly CP, Hansen J, Bosch JA, Wei G, Paster BJ, Schuppan D, Helmerhorst EJ.

Appl Environ Microbiol. 2017 Mar 2;83(6). pii: e03330-16. doi: 10.1128/AEM.03330-16. Print 2017 Mar 15.

43.

Prospective randomized controlled study on the effects of Saccharomyces boulardii CNCM I-745 and amoxicillin-clavulanate or the combination on the gut microbiota of healthy volunteers.

Kabbani TA, Pallav K, Dowd SE, Villafuerte-Galvez J, Vanga RR, Castillo NE, Hansen J, Dennis M, Leffler DA, Kelly CP.

Gut Microbes. 2017 Jan 2;8(1):17-32. doi: 10.1080/19490976.2016.1267890. Epub 2016 Dec 14.

44.

No Difference Between Latiglutenase and Placebo in Reducing Villous Atrophy or Improving Symptoms in Patients With Symptomatic Celiac Disease.

Murray JA, Kelly CP, Green PHR, Marcantonio A, Wu TT, Mäki M, Adelman DC; CeliAction Study Group of Investigators.

Gastroenterology. 2017 Mar;152(4):787-798.e2. doi: 10.1053/j.gastro.2016.11.004. Epub 2016 Nov 15.

PMID:
27864127
45.

The Monoclonal Antitoxin Antibodies (Actoxumab-Bezlotoxumab) Treatment Facilitates Normalization of the Gut Microbiota of Mice with Clostridium difficile Infection.

Džunková M, D'Auria G, Xu H, Huang J, Duan Y, Moya A, Kelly CP, Chen X.

Front Cell Infect Microbiol. 2016 Oct 4;6:119. eCollection 2016.

46.

Probiotic Saccharomyces boulardii CNCM I-745 prevents outbreak-associated Clostridium difficile-associated cecal inflammation in hamsters.

Koon HW, Su B, Xu C, Mussatto CC, Tran DH, Lee EC, Ortiz C, Wang J, Lee JE, Ho S, Chen X, Kelly CP, Pothoulakis C.

Am J Physiol Gastrointest Liver Physiol. 2016 Oct 1;311(4):G610-G623. doi: 10.1152/ajpgi.00150.2016. Epub 2016 Aug 11.

47.

Creation of a model to predict survival in patients with refractory coeliac disease using a multinational registry.

Rubio-Tapia A, Malamut G, Verbeek WH, van Wanrooij RL, Leffler DA, Niveloni SI, Arguelles-Grande C, Lahr BD, Zinsmeister AR, Murray JA, Kelly CP, Bai JC, Green PH, Daum S, Mulder CJ, Cellier C.

Aliment Pharmacol Ther. 2016 Oct;44(7):704-14. doi: 10.1111/apt.13755. Epub 2016 Aug 3.

48.

The association between socioeconomic status and the symptoms at diagnosis of celiac disease: a retrospective cohort study.

Roy A, Mehra S, Kelly CP, Tariq S, Pallav K, Dennis M, Peer A, Lebwohl B, Green PH, Leffler DA.

Therap Adv Gastroenterol. 2016 Jul;9(4):495-502. doi: 10.1177/1756283X16637532. Epub 2016 Mar 18.

49.

Serum I-FABP Detects Gluten Responsiveness in Adult Celiac Disease Patients on a Short-Term Gluten Challenge.

Adriaanse MP, Leffler DA, Kelly CP, Schuppan D, Najarian RM, Goldsmith JD, Buurman WA, Vreugdenhil AC.

Am J Gastroenterol. 2016 Jul;111(7):1014-22. doi: 10.1038/ajg.2016.162. Epub 2016 May 17.

PMID:
27185075
50.

The burden of clostridium difficile infection: estimates of the incidence of CDI from U.S. Administrative databases.

Olsen MA, Young-Xu Y, Stwalley D, Kelly CP, Gerding DN, Saeed MJ, Mahé C, Dubberke ER.

BMC Infect Dis. 2016 Apr 22;16:177. doi: 10.1186/s12879-016-1501-7.

Supplemental Content

Loading ...
Support Center